Illustration of a shift from a crossed-out, torn-paper shape to hands adjusting an organised gear system on a blue and pink background, suggesting the move from the old PCOS label to a clearer PMOS understanding.

PMOS is here — the new name for polycystic ovary syndrome (PCOS)

Polycystic ovary syndrome (PCOS) has just been officially renamed polyendocrine metabolic ovarian syndrome (PMOS). If you have PMOS (or a PCOS diagnosis recorded in your notes), you may be wondering what this means for you. The short answer: your condition hasn’t changed — but the name finally reflects what’s actually going on in your body.

Why Was the Name Changed?

The old name, polycystic ovary syndrome (PCOS), has long been recognised as misleading, even by the medical community. The term “polycystic” implies that your ovaries are full of cysts — but they’re not. What ultrasound actually shows are small follicles (fluid-filled sacs each containing an immature egg) that haven’t developed normally, not pathological cysts. The old name caused real harm: it confused patients, confused clinicians, and delayed diagnoses for countless people.

The rename is the result of an extraordinary global effort — one of the largest medical naming consensus processes ever undertaken. Over 14,000 patients and health professionals from around the world participated in surveys, workshops, and expert panels over several years, culminating in a landmark paper published in The Lancet in May 2026. The new name, polyendocrine metabolic ovarian syndrome (PMOS), was agreed upon by an overwhelming majority.

What Does PMOS Actually Mean?

Let’s break down the new name, because each word earns its place:

Poly-endocrine — PMOS is a condition involving multiple hormonal (endocrine) disturbances, not just one. It affects insulin, androgens (male-type hormones), and reproductive hormones all at once. These systems interact with each other in a complex, self-reinforcing way.

Metabolic — The metabolic effects of PMOS are just as important as the reproductive ones. Insulin resistance is present in the majority of people with PMOS — including in those who are a healthy weight. This drives a higher risk of type 2 diabetes, high blood pressure, high cholesterol, fatty liver disease, and cardiovascular disease.

Ovarian — The ovaries are still central to the condition. Disrupted follicle development, elevated anti-Müllerian hormone (AMH), irregular or absent ovulation, and menstrual irregularity are all key features that originate in ovarian dysfunction.

Syndrome — PMOS is a syndrome, meaning it’s a collection of features that don’t all need to be present at once, and that can look quite different from person to person.

What Are the Symptoms?

PMOS can look very different between individuals, and it changes throughout your life. Common features include:

  • Irregular or absent periods — due to infrequent ovulation
  • Signs of excess androgens — acne, unwanted facial or body hair (hirsutism), or hair thinning on the scalp
  • Difficulty getting pregnant — PMOS is one of the most common causes of female infertility, though many women with PMOS do conceive
  • Weight changes — PMOS makes it harder to lose weight and easier to gain it, due to the underlying metabolic changes
  • Mood and mental health — higher rates of anxiety, depression, and disordered eating are associated with PMOS
  • Polycystic-appearing ovaries on ultrasound, or elevated AMH on a blood test

You do not need all of these features to be diagnosed. In New Zealand, as elsewhere, diagnosis follows international guidelines requiring just two of three criteria: signs of high androgens, irregular ovulation, or the ovarian appearance on ultrasound or AMH.

What Does This Mean in New Zealand?

Globally, around 1 in 8 women have PMOS — and up to 70% remain undiagnosed. In Aotearoa, this is a real issue. People with PMOS often go years without a diagnosis, receiving fragmented care that treats symptoms (acne from a dermatologist, irregular periods from a GP, infertility from a fertility specialist) without connecting them to a single underlying condition.

Renaming the condition matters here because:

  • It opens better conversations. A name that says hormonal and metabolic signals to both patients and GPs that this requires a whole-of-health approach — not just a referral to gynaecology.
  • It reduces stigma. Many people report distress associated with a name that implies something is wrong with their ovaries specifically, particularly when fertility is involved. PMOS removes that focus.
  • It may improve research and funding pathways — conditions with clearer, more accurate names tend to attract more consistent research interest and health system investment.

The transition to the new name will happen over three years, so you’ll hear both PCOS and PMOS used during this period. For ICD coding, electronic health records, and international guidelines, the changeover is actively underway.

How Is PMOS Managed?

There is no cure, but PMOS is very manageable — and treatment is tailored to what matters most to you at this point in your life.

  • Lifestyle — Even modest improvements in diet and physical activity can meaningfully reduce insulin resistance, restore ovulation, and improve symptoms. This isn’t about weight alone; metabolic health is the goal.
  • Hormonal contraception — Combined oral contraceptives regulate cycles and reduce androgen-related symptoms like acne and excess hair.
  • Metformin — An insulin-sensitising medication that can help with metabolic features and, in some cases, restore ovulation.
  • Ovulation induction — For women trying to conceive, medications such as letrozole or clomiphene can stimulate ovulation. Many women with PMOS go on to have successful pregnancies. Treatment may be funded and afordable to self-fund.
  • Newer weight-loss medications — GLP-1 receptor agonists (such as semaglutide) are showing promise for PMOS, and clinical trials are ongoing.
  • Long-term monitoring — Because of the metabolic risks, regular checks for blood pressure, blood glucose, and lipids are an important part of ongoing care.

A Final Note

I see many patients in both my Ponsonby and Pukekohe clinics who have spent years confused, misinformed, or partially treated because of the inadequacy of the old PCOS label. Women who were told they “just have a few cysts” and sent away. People who didn’t recognise themselves in the name because they didn’t have irregular periods, or because their ultrasound looked normal.

The rename to PMOS is, in my view, long overdue and genuinely meaningful. It correctly frames this condition as a multisystem hormonal disorder — one that deserves coordinated, longitudinal care. If you’ve been diagnosed with PMOS (or are still recorded under PCOS) and feel like your care has been incomplete, I’d encourage you to get in touch. A fresh conversation with the right framework can make a real difference.

This post is based on the global consensus paper published in The Lancet on 12 May 2026 Teede et al., “Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process” and associated patient information published by The Guardian.

Published: 2026-05-14